Companies / TG Therapeutics Inc

TG Therapeutics Inc

Nasdaq: TGTXCIK 1001316NEW YORK, NYtgtherapeutics.com

Financials · FY2025

Revenue$616.29M
Net income$447.18M
Total debt$745.39M
Cash$482.57M
Diluted EPS$2.77
Shares outstanding153.1M

Ownership

153.1M shares outstanding · as of Aug 3, 2026
7.0%Insiders
Ownership
Insiders7.03%10,755,887
10%+ / strategic5.49%8,400,210
Institutions67.21%102,872,991
Public float20.28%31,039,965

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
Weiss Michael SCEOCEO · Director
6.39%9,778,086
0.52%798,111
0.12%179,690
Hume DanielDirector
Lonial SagarDirector

Institutional holders 363

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jan 8, 2026Power Sean A
Executive
GrantCommon Stock$0+90K
+12.71%
798,111
0.52% of shares
low
Jan 29, 2026Charney Laurence N
Director
GiftCommon Stock$0-13K
-6.84%
179,690
0.12% of shares
low
Jan 28, 2026Charney Laurence N
Director
GiftCommon Stock$0-30K
-13.46%
192,887
0.13% of shares
low
Jan 8, 2026Weiss Michael S
CEO
GrantCommon Stock$0+622K
+6.79%
9,778,086
6.39% of shares
low
Jun 11, 2026Lonial Sagar
Director
GrantStock Tracking Unit+8K
8,325
<0.01% of shares
low
Jun 11, 2026Hume Daniel
Director
GrantStock Tracking Unit+8K
8,325
<0.01% of shares
low
Jun 11, 2026Hoberman Kenneth
Director
GrantStock Tracking Unit+8K
8,325
<0.01% of shares
low
Jun 11, 2026Echelard Yann
Director
GrantStock Tracking Unit+8K
8,325
<0.01% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A0
Vanguard Portfolio ManagementPassive13G8,400,210

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TGTX88322Q108